How a rare kidney disease gained a robust new therapy pipeline

In December 2021, the FDA approved the first therapy indicated to treat primary immunoglobulin A nephropathy. Since then, several novel drugs have received accelerated approval for the disease, and more are in the pipeline.“In just the last few years, there’s been an explosion in therapies available to us,” Jackson Kim, MD, clinical assistant professor in the division of

Raccontata dahealio.com